NCT06084624View on ClinicalTrials.gov

Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

April 30, 2025

Conditions
Oral Ulceration Due to Behçet's Disease
Interventions
DRUG

Rebamipide mouthwash

Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinone-4-yl\]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome

DRUG

Betamethasone mouthwash

Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers

All Listed Sponsors
lead

Cairo University

OTHER

NCT06084624 - Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease | Biotech Hunter | Biotech Hunter